Core Insights - Sera Prognostics Inc. announced the appointment of Jeff Elliott to its Board of Directors, effective March 20, 2025, while Ryan Trimble will retire on June 30, 2025, after 14 years with the company [1][2] - The company is focused on improving maternal and neonatal health through innovative pregnancy biomarker information, particularly with its PreTRM® test [1][4] Company Developments - Jeff Elliott brings extensive experience in corporate strategy, business operations, and commercializing molecular diagnostics, which will aid Sera in leveraging recent PRIME study results for market building [2][3] - Ryan Trimble expressed confidence in the company's direction and the successful completion of the PRIME study, indicating a strong foundation for future growth [3] Product Information - Sera Prognostics specializes in precision pregnancy care, aiming to reduce healthcare delivery costs through early prediction of preterm birth risk and other pregnancy complications [4] - The PreTRM® Test is a validated blood-based biomarker test that predicts the risk of spontaneous preterm birth, allowing for personalized clinical decisions [7]

Core Viewpoint - Sera Prognostics Inc. reported its financial results for Q4 and full year 2024, highlighting a decrease in revenue and net loss, while emphasizing progress in its PRIME study and recent fundraising efforts to support its mission in maternal and neonatal health [1][3]. Financial Results Summary Fourth Quarter 2024 - Revenue for Q4 2024 was $24,000, down from $41,000 in Q4 2023 [4]. - Total operating expenses increased to $9.4 million, a 6% rise from $8.9 million in Q4 2023 [4]. - Research and development expenses were $3.1 million, a decrease of approximately 19% compared to Q4 2023 [5]. - Selling, general and administrative expenses rose to $6.3 million from $5.0 million in Q4 2023, driven by increased spending on commercial activities [5]. - The net loss for the quarter was $8.6 million, compared to $7.9 million in the prior-year quarter [5]. Full Year 2024 - Total revenue for the full year 2024 was $77,000, down from $306,000 in 2023 [6]. - Total operating expenses decreased to $36.7 million from $40.1 million in 2023 [6]. - Research and development expenses for 2024 were $14.7 million, down from $15.2 million in 2023 [8]. - Selling, general and administrative expenses for 2024 were $21.9 million, significantly reduced from $24.7 million in 2023 [8]. - The net loss for 2024 was $32.9 million, down from $36.2 million in 2023 [8]. PRIME Study Results - The PRIME study demonstrated a 25% reduction in neonatal morbidity and mortality index (NMI) and an 18% reduction in neonatal length of hospital stay among the modified intent-to-treat population [7]. - A broader intent-to-treat population showed a 20% reduction in NMI and a 22% reduction in NICU admissions [7]. Fundraising and Future Plans - The company raised $57.5 million through a public follow-on offering in February 2025, extending its cash runway through 2028 [7][9]. - Proceeds will be used to expand commercial efforts in selected U.S. geographies, partner with payers and providers, and prepare for expansion in the European Union [7]. Company Overview - Sera Prognostics is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [1][11]. - The PreTRM® Test is a key product that provides early risk prediction for spontaneous preterm birth, enabling proactive interventions [11][13].

SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results ...

SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss S ...

SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock.  In add ...

Event will showcase results of Company's pivotal PRIME study and include the principal investigatorSALT LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. This date was changed from the prior planned date ...

Core Insights - Sera Prognostics, Inc. announced that the results of the PRIME study will be presented at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting on January 31, 2025 [1][2] - The PRIME study evaluated the effectiveness of the PreTRM test in identifying pregnant women at higher risk of preterm delivery and its impact on neonatal outcomes [2][4] - The PreTRM test is a blood-based biomarker test that provides individualized risk predictions for spontaneous preterm birth [6] Company Overview - Sera Prognostics is dedicated to improving maternal and neonatal health through innovative diagnostic tests aimed at early prediction of preterm birth risk [4] - The company is headquartered in Salt Lake City, Utah, and focuses on precision pregnancy care to reduce healthcare delivery costs [4] Study Details - The PRIME study, which stands for Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal Outcomes, achieved at least one primary endpoint at the required statistical significance level during its interim analysis [2] - The study's enrollment was halted in December 2023, and the company has since concentrated on data gathering and analysis for the complete cohort [2] Industry Context - Preterm birth is defined as any birth before 37 weeks' gestation and is a leading cause of illness and death in newborns [5] - The March of Dimes Report Card indicates that over 10% of infants in the U.S. are born prematurely, with significant long-term medical complications associated with prematurity [5] - The annual healthcare costs for managing complications of prematurity in the U.S. were estimated at approximately $25 billion in 2016 [5]

Core Viewpoint - Sera Prognostics Inc. is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information, and will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 [1] Company Overview - Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care [3] - The company aims to provide early, pivotal pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera has a robust pipeline of innovative diagnostic tests aimed at early prediction of preterm birth risk and other pregnancy complications [3] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns [4] - Over the last five years, more than one in ten infants in the United States has been born prematurely [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion for 2016 [4] PreTRM® Test Details - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test measures and analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify women at increased risk during weeks 18 through 20 of pregnancy [5] - The PreTRM® Test enables more informed, personalized clinical decisions based on each woman's individual risk [5]

SALT LAKE CITY, Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and d ...

Sera Prognostics Inc (NASDAQ:SERA) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes. I would now li ...